Clinicopathological Study of Triple Negative Breast Cancers

Ishitha, Gunadala; Manipadam, Marie Therese; Backianathan, Selvamani; Chacko, Raju Titus; Abraham, Deepak Thomas; Jacob, Paul

doi:10.7860/jcdr/2016/20475.8539

Cited by 4 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 As compared to our findings show low grade in 32.1% and high grade in 67.9% patients with TNBC, Atika Dogra et al [15] revealed that a large proportion of patients with poorly differentiated high grade tumors (70%). Comparative findings were seen in a study by Ishitha G. et al [12] shows 46% cases had Grade II and 54% had Grade III tumors on histology as. Regarding surgical interventions, in comparison to our study (MRM in 69.1% and BCS in 29.7% cases), MRM was performed in lesser number of cases in comparison with the study by Atika Dogra et al [15] (MRM in 80.6% and BCS 16.4% cases).…”

Section: Resultssupporting

confidence: 52%

“…Our population was slightly younger than the ones described in western data [10] (median age 53 years). As compared to mean size of tumor in our study (3.6±1.94cm), Ishitha G. et al [12] found average size tumor was 4.3±2.56 cm. Higher number of patients had Positive family in study by Ishitha G. et al [12] (12%) as compared to our study (4.8%).…”

Section: Epidemiological Profilesupporting

confidence: 43%

See 1 more Smart Citation

Epidemiological Profile and Clinicopathological Correlates of Triple Negative Breast Cancer Patients at Regional Cancer Centre

Verma

Jakhar

Sharma

et al. 2021

Asian Pac J Cancer Care

View full text Add to dashboard Cite

Background: Breast Cancer is the most common cancer among woman worldwide. In India breast cancer remains the leading cause of both incidence and mortality. Triple negative breast cancer is more difficult to treat as it does not respond to hormone therapy medicines or medicines that target receptor proteins (like HER 2 Neu). It is crucial for the physician to know the status of the disease as the patient can be subjected to a whole new avenue of treatment. The present study was done to assess the epidemiological profile and clinicopathological correlates of patients of triple negative breast cancer. Material and Methods: This retrospective study was carried out in Acharya Tulsi Cancer and Research Institute located in the state of Rajasthan, Bikaner, India, among Ca Breast patients presenting to Medical Oncology, Radiation Oncology and Surgical Oncology outdoor & indoor from April 2016 to March 2017. Out of the total 1017 patients of carcinoma breast 957 were included in this Study. Exclusion criteria was non availability of ER, PR, HER2 neu status reports because of various reasons like affordability. Out of the total 957 patients 249 were found to be triple negative. Statistical analysis was done using IBM SPSS version 21. Results: Mean age of the patients was 46±11.23 years. Out of total 249 patients of triple negative breast carcinoma, 91 (%) were found to have had clinical staging I and II (Early stage) and 158 (%) patients were found to have clinical staging III & IV (Late Stage). Mean size of the tumor was 3.6±1.94cm. 151 (60.6%) were pre-menopausal, 103 (41.4%) and 12 (4.8%) patients had positive family history. All of or patients diagnosed to have Ductal type of carcinoma. Lympho-vascular invasion was seen in 51 (20.5%) patients and High grade Histological Grading was seen in High Grade 169 (67.9%) patients. 172 (69.1%) undergone MRM (Modified Radical Mastectomy) and BCS was done in 74 (29.7%) patients. After comparison of triple Negative Breast Cancer with non-triple Negative Breast Cancer, lower age, later stages (III and IV), pre-menopausal status and high grade (on histology) were significantly more in negative type of Ca breast. Occurrence of early Menarche (< 13 Years) and history of OC pills used was almost equal in both the groups. Conclusion: Triple Negative Breast Cancer was found to present at an earlier age and more in pre – menopausal women. Such patients presented with a higher histological grade of tumor and late stage of presentation. There was no statistically significant association between TNBC and age of menarche, use of OC pill, previous exposure to radiotherapy and positive family history in first degree relative.

show abstract

Section: Resultssupporting

confidence: 52%

Section: Epidemiological Profilesupporting

confidence: 43%

Epidemiological Profile and Clinicopathological Correlates of Triple Negative Breast Cancer Patients at Regional Cancer Centre

Verma

Jakhar

Sharma

et al. 2021

Asian Pac J Cancer Care

View full text Add to dashboard Cite

show abstract

“…Non luminal tumours can be classified into the HER2 subtype and the triple negative (TN) subtype. Based on expression of basal markers, TN can be further subdivided into the basal phenotype and the non basal or five negative phenotype [ 5,10,15,22 ]. Basal marker expression in TN breast cancers has been extensively studied.…”

Section: Introductionmentioning

confidence: 99%

Basal markers and prognosis in luminal breast cancer

Engstrøm

Valla

Bofin

2017

Breast Cancer Res Treat

View full text Add to dashboard Cite

PurposeBasal marker expression in triple negative breast cancers identifies basal like tumours, and thus separates the TN group into two prognostic groups. However, the expression and prognostic significance of basal markers in luminal breast cancers are poorly described. The aim of this study was to investigate the expression and prognostic value of basal markers (CK5, CK14 and EGFR) in luminal breast cancer.

show abstract

“…Triple-negative tumors are primarily defined, therefore, by an absence of surrogate markers of relevance for individualized therapy. As has been shown in numerous studies, triple-negative tumors vary in tumor progression, the development of therapeutic resistance, and the clinical course 10 , 11 , 12 , 13 , 14 , 15 , which indicates that they comprise a heterogeneous group. Further characterization and subtyping of triple-negative tumors on the basis of therapeutically relevant biomarkers is therefore strongly necessary.…”

Section: Introductionmentioning

confidence: 81%

Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression

et al. 2018

View full text Add to dashboard Cite

Background: "Triple-negative breast cancers" (TNBC) comprise a heterogeneous group of about 15% of invasive BCs lacking the expression of estrogen and progesterone receptors (ER, PR) and the expression of HER2 (ERBB2) and are therefore no established candidates for targeted treatment options in BC, i.e., endocrine and anti-HER2 therapy. The aim of the present study was to use gene expression profiling and immunohistochemical (IHC) characterization to identify receptor tyrosine kinase (RTK) profiles that would allow patient stratification for the purposes of target-oriented personalized tumor therapy in TNBC.Methods: Twenty-nine cases of TNBC selected according to routine diagnostic IHC/cytogenetic criteria were examined by reverse transcription polymerase chain reaction (RT-PCR). RTK mRNA expression profiles were generated for a total of 31 tumor-relevant biomarkers, mainly belonging to the IGF- and EGF-receptor families but also including biomarkers related to downstream signaling. Protein expression of selected biomarkers was investigated by IHC.Results: Hierarchical cluster analysis revealed a dichotomous differentiation pattern amongst TNBCs. A significant difference in gene expression was observed for 16 of the 31 RTK-associated tumor relevant biomarkers between the two newly identified TNBC subgroups. The findings were verified at the posttranslational level by the IHC data. The RTKs HER4, IGF-1R and IGF-2R and the hormone receptors ER and PR below the IHC detection limit play a central role in the differentiation of the two TNBC subgroups. Observed survival was reported as Kaplan-Meier estimates and point towards an improved survival of patients with RTK-high with superior three-year survival rate of 100% compared to RTK-low gene signatures with superior three-year survival rate of 60% (log-rank test, p-value = 0.022).Conclusion: Gene-expression and IHC analysis of the EGF and IGF receptor families and biomarkers associated with downstream signaling point to the existence of two distinct TNBC subtypes. The RTKs HER4, IGF-1R, IGF-2R and the hormone receptors ER and PR appear to be of particular importance here. Based on survival analysis the differentiation of TNBC with RTK-high and RTK-low gene signatures seems to be of prognostic relevance. Additionally, correlation analysis of the relationship between RTKs and ER suggests co-regulatory mechanisms that may have potential significance in new therapeutic approaches.

show abstract

Clinicopathological Study of Triple Negative Breast Cancers

Cited by 4 publications

References 36 publications

Epidemiological Profile and Clinicopathological Correlates of Triple Negative Breast Cancer Patients at Regional Cancer Centre

Epidemiological Profile and Clinicopathological Correlates of Triple Negative Breast Cancer Patients at Regional Cancer Centre

Basal markers and prognosis in luminal breast cancer

Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression

Contact Info

Product

Resources

About